Delaware (State or other jurisdiction of incorporation or organization)

13-3986004 (I.R.S.  Employer Identification No.)

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	SSKN	The NASDAQ Stock Market LLC

	Large accelerated filer [  ]		Accelerated filer [  ]
	Non-accelerated filer [x]		Smaller reporting company [x]
	Emerging growth company [  ]

Part I. Financial Information:			PAGE
	ITEM 1.  Financial Statements:
	a.	Condensed Consolidated Balance Sheets as of September 30, 2020 (unaudited) and December 31, 2019	1
	b.	Condensed Consolidated Statements of Operations for the three months ended September 30, 2020 and, 2019 (unaudited)	2
	c.	Condensed Consolidated Statements of Operations for the nine months ended September 30, 2020 and, 2019 (unaudited)	3
	d.	Condensed Consolidated Statement of Changes in Stockholders’ Equity for the nine months ended September 30, 2019 (unaudited)	4
	e.	Condensed Consolidated Statement of Changes in Stockholders’ Equity for the nine months ended September 30, 2020 (unaudited)	5
	f.	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and, 2019 (unaudited)	6
	g.	Notes to Unaudited Condensed Consolidated Financial Statements	7
	ITEM 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations		23
	ITEM 3.  Quantitative and Qualitative Disclosure about Market Risk		32
	ITEM 4.  Controls and Procedures		32
Part II. Other Information:
	ITEM 1.  Legal Proceedings		33
	ITEM 1A.  Risk Factors		33
	ITEM 2.  Unregistered Sales of Equity Securities and Use of Proceeds		33
	ITEM 3.  Defaults Upon Senior Securities		33
	ITEM 4.  Mine Safety Disclosures		33
	ITEM 5.  Other Information		33
	ITEM 6.  Exhibits		33
		Signatures	34
		Certifications	E-31.1

		September 30, 2020				December 31, 2019
ASSETS		(unaudited)
Current assets:
Cash and cash equivalents		$	11,063			$	8,129
Restricted cash			7,397				7,500
Accounts receivable, net of allowance for doubtful accounts of $249 and $184, respectively			2,510				4,386
Inventories			3,502				3,027
Prepaid expenses and other current assets			464				513
Total current assets			24,936				23,555
Property and equipment, net			5,258				5,369
Operating lease right-of-use assets, net			1,072				1,314
Intangible assets, net			6,697				7,955
Goodwill			8,803				8,803
Other assets			298				347
Total assets		$	47,064			$	47,343
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Note payable		$	7,275			$	7,275
Current portion of long-term debt			1,134				-
Accounts payable			3,488				1,880
Other accrued liabilities			4,558				5,134
Current portion of operating lease liabilities			361				313
Deferred revenues			1,864				2,832
Total current liabilities			18,680				17,434
Long-term liabilities:
Long-term debt, net			1,394				-
Deferred tax liability			207				-
Long-term operating lease liabilities, net			804				1,078
Other liabilities			52				178
Total liabilities			21,137				18,690
Commitments and contingencies (see Note 15)
Stockholders' equity:
Series C Convertible Preferred Stock, $.10 par value, 10,000,000 shares authorized; 0 and 2,103 shares issued and outstanding at September 30, 2020 and, December 31, 2019, respectively			-				1
Common Stock, $.001 par value, 150,000,000 shares authorized; 33,754,909 and 32,932,273 shares issued and outstanding at September 30, 2020 and, December 31, 2019, respectively			34				33
Additional paid-in capital			244,423				243,180
Accumulated deficit			(218,530	)			(214,561	)
Total stockholders' equity			25,927				28,653
Total liabilities and stockholders’ equity		$	47,064			$	47,343

		For the Three Months Ended September 30,
		2020				2019
Revenues, net		$	5,613			$	7,480
Cost of revenues			2,383				2,855
Gross profit			3,230				4,625
Operating expenses:
Engineering and product development			411				249
Selling and marketing			2,051				2,887
General and administrative			1,929				2,218
			4,391				5,354
Loss from operations			(1,161	)			(729	)
Other expense, net:
Interest expense, net			(21	)			(153	)
			(21	)			(153	)
Loss before income taxes			(1,182	)			(882	)
Income tax (expense) benefit			(72	)			22
Net loss		$	(1,254	)		$	(860	)
Loss attributable to common shares		$	(1,254	)		$	(840	)
Loss attributable to Series C Convertible Preferred shares		$	-			$	(20	)
Loss per common share:
Basic		$	(0.04	)		$	(0.03	)
Diluted		$	(0.04	)		$	(0.03	)
Shares used in computing loss per common share:
Basic			33,754,909				32,903,287
Diluted			33,754,909				32,903,287
Loss per Series C Convertible Preferred share basic and diluted		$	-			$	(9.58	)
Shares used in computing loss per basic and diluted Series C Convertible Preferred shares			-				2,103

		For the Nine Months Ended September 30,
		2020				2019
Revenues, net		$	16,373			$	22,688
Cost of revenues			6,780				8,544
Gross profit			9,593				14,144
Operating expenses:
Engineering and product development			950				788
Selling and marketing			6,446				8,911
General and administrative			5,921				7,398
			13,317				17,097
Loss from operations			(3,724	)			(2,953	)
Other expense, net:
Interest expense, net			(38	)			(433	)
			(38	)			(433	)
Loss before income taxes			(3,762	)			(3,386	)
Income tax (expense) benefit			(207	)			111
Net loss		$	(3,969	)		$	(3,275	)
Loss attributable to common shares		$	(3,947	)		$	(3,079	)
Loss attributable to Series C Convertible Preferred shares		$	(22	)		$	(196	)
Loss per common share:
Basic		$	(0.12	)		$	(0.10	)
Diluted		$	(0.12	)		$	(0.10	)
Shares used in computing loss per common share:
Basic			33,551,070				31,663,355
Diluted			33,551,070				31,663,355
Loss per Series C Convertible Preferred share basic and diluted		$	(43.73	)		$	(36.14	)
Shares used in computing loss per basic and diluted Series C Convertible Preferred shares			491				5,412

		Convertible Preferred Stock – Series C								Common Stock								Additional Paid-In				Accumulated
		Shares				Amount				Shares				Amount				Capital				Deficit				Total
BALANCE, January 1, 2019			9,968			$	1				29,943,086			$	30			$	241,988			$	(210,771	)		$	31,248
Stock-based compensation			-				-				-				-				323				-				323
Conversion of convertible preferred stock into common stock			(3,090	)			-				1,148,698				1				(1	)			-				-
Exercise of stock options			-				-				28,824				-				-				-				-
Net loss			-				-				-				-				-				(1,333	)			(1,333	)
BALANCE, March 31, 2019			6,878			$	1				31,120,608			$	31			$	242,310			$	(212,104	)		$	30,238

Conversion of convertible preferred stock into common stock			(4,775	)			-				1,775,093				2				(2	)			-				-
Stock-based compensation			-				-				-				-				303				-				303
Exercise of stock options			-				-				7,586				-				-
Net loss			-				-				-				-				-				(1,082	)			(1,082	)
BALANCE, June 30, 2019			2,103			$	1				32,903,287			$	33			$	242,611			$	(213,186	)		$	29,459
Stock based compensation			-				-				-				-				257				-				257
Net loss			-				-				-				-				-				(860	)			(860	)
BALANCE, September 30, 2019			2,103			$	1				32,903,287			$	33			$	242,868			$	(214,046	)		$	28,856

		Convertible Preferred Stock – Series C								Common Stock								Additional Paid-In				Accumulated
		Shares				Amount				Shares				Amount				Capital				Deficit				Total
BALANCE, January 1, 2020			2,103			$	1				32,932,273			$	33			$	243,180			$	(214,561	)		$	28,653
Stock-based compensation			-				-				-				-				430				-				430
Conversion of convertible preferred stock into common stock			(2,103	)			(1	)			782,089				1				-				-				-
Net loss			-				-				-				-				-				(1,035	)			(1,035	)
BALANCE, March 31, 2020			-			$	-				33,714,362			$	34			$	243,610			$	(215,596	)		$	28,048
Stock-based compensation			-				-								-				410				-				410
Issuance of restricted stock			-				-				40,547				-				-				-				-
Net loss			-				-				-				-				-				(1,680	)			(1,680	)
BALANCE, June 30, 2020			-			$	-				33,754,909			$	34			$	244,020			$	(217,276	)		$	26,778
Stock based compensation			-				-				-				-				403				-				403
Net loss			-				-				-				-				-				(1,254	)			(1,254	)
BALANCE, September 30, 2020			-			$	-				33,754,909			$	34			$	244,423			$	(218,530	)		$	25,927

		For the Nine Months Ended September 30,
		2020				2019
Cash Flows From Operating Activities:
Net loss		$	(3,969	)		$	(3,275	)
Adjustments to reconcile net loss to net cash provided by  operating activities:
Depreciation and amortization			2,793				3,437
Amortization of right-of-use asset			242				240
Provision for doubtful accounts			65				9
Loss on disposal of property and equipment and lasers placed in service			23				29
Stock-based compensation			1,243				883
Deferred taxes			207				(111	)
Amortization of debt discount			-				43
Amortization of deferred financing costs			-				64
Changes in operating assets and liabilities:
Accounts receivable			1,811				(261	)
Inventories			(475	)			(792	)
Prepaid expenses and other assets			98				76
Accounts payable			1,608				233
Other accrued liabilities			(576	)			437
Other liabilities			(126	)			(61	)
Operating lease liabilities			(226	)			(219	)
Deferred revenues			(968	)			384
Net cash provided by operating activities			1,750				1,116
Cash Flows From Investing Activities:
Lasers placed-in-service			(1,430	)			(1,370	)
Purchases of property and equipment			(17	)			(5	)
Net cash used in investing activities			(1,447	)			(1,375	)
Cash Flows From Financing Activities:
Proceeds from note payable and long-term debt			2,528				-
Net cash provided by financing activities			2,528				-
Net increase (decrease) in cash and cash equivalents and restricted  cash			2,831				(259	)
Cash, cash equivalents and restricted cash, beginning of period			15,629				16,487
Cash, cash equivalents and restricted cash, end of period		$	18,460			$	16,228
Cash and cash equivalents		$	11,063			$	16,228
Restricted cash			7,397				-
		$	18,460			$	16,228
Supplemental information of cash and non-cash transactions:
Cash paid for interest		$	157			$	604
Lease liabilities arising from obtaining right-of-use assets		$	-			$	1,632

	•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
	•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
	•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors.

		Three Months Ended September 30, 2020								Nine Months Ended September 30, 2020
		Common Stock				Series C Convertible Preferred Stock				Common Stock				Series C Convertible Preferred Stock
Loss attributable to each class		$	(1,254	)		$	-			$	(3,947	)		$	(22	)
Weighted average number of shares outstanding during the period			33,754,909				-				33,551,070				491
Basic and Diluted loss per share		$	(0.04	)		$	-			$	(0.12	)		$	(43.73	)

		Three Months Ended September 30, 2019								Nine Months Ended September 30, 2019
		Common Stock				Series C Convertible Preferred Stock				Common Stock				Series C Convertible Preferred Stock
Loss attributable to each class		$	(840	)		$	(20	)		$	(3,079	)		$	(196	)
Weighted average number of shares outstanding during the period			32,903,287				2,105				31,663,355				5,412
Basic and Diluted loss per share		$	(0.03	)		$	(9.58	)		$	(0.10	)		$	(36.14	)

		Three Months Ended September 30,				Nine Months Ended September 30,
		2020		2019		2020		2019
Common stock purchase warrants		149,901		1,073,319		530,923		1,776,216
Restricted stock units		119,330		120,773		149,637		123,675
Common stock options		4,908,038		4,033,038		4,908,038		4,178,663
Total		5,177,269		5,227,130		5,588,598		6,078,554

		Three Months Ended September 30, 2020
		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Domestic		$	3,690			$	261			$	3,951
Foreign			145				1,517				1,662
Total		$	3,835			$	1,778			$	5,613

		Nine Months Ended September 30, 2020
		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Domestic		$	11,957			$	701			$	12,658
Foreign			375				3,340				3,715
Total		$	12,332			$	4,041			$	16,373

		Three Months Ended September 30, 2019
		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Domestic		$	5,991			$	241			$	6,232
Foreign			-				1,248				1,248
Total		$	5,991			$	1,489			$	7,480

		Nine Months Ended September 30, 2019
		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Domestic		$	17,142			$	943			$	18,085
Foreign			-				4,603				4,603
Total		$	17,142			$	5,546			$	22,688

Remaining 2020		$	148
2021			618
2022			618
2023			551
2024			267
Thereafter			2
Total		$	2,204

		September 30, 2020				December 31, 2019
Raw materials and work-in-process		$	3,071			$	2,651
Finished goods			431				376
Total inventories		$	3,502			$	3,027

		September 30, 2020				December 31, 2019
Lasers placed-in-service		$	22,239			$	20,925
Equipment, computer hardware and software			146				146
Furniture and fixtures			234				234
Leasehold improvements			43				26
			22,662				21,331
Accumulated depreciation and amortization			(17,404	)			(15,962	)
Property and equipment, net		$	5,258			$	5,369

		Balance				Accumulated Amortization				Intangible assets, net
Core technology		$	5,700			$	(2,993	)		$	2,707
Product technology			2,000				(2,000	)			-
Customer relationships			6,900				(3,623	)			3,277
Tradenames			1,500				(787	)			713
		$	16,100			$	(9,403	)		$	6,697

Remaining 2020		$	352
2021			1,410
2022			1,410
2023			1,410
2024			1,410
2025			705
Total		$	6,697

		September 30, 2020				December 31, 2019
Accrued warranty, current		$	107			$	170
Accrued compensation, including commissions and vacation			780				1,193
Accrued state sales, use and other taxes			3,094				3,193
Accrued professional fees and other accrued liabilities			577				578
Total other accrued liabilities		$	4,558			$	5,134

		Three Months Ended, September 30,								Nine Months Ended, September 30,
		2020				2019				2020				2019
Accrual at beginning of period		$	139			$	291			$	232			$	238
Additions charged to warranty expense			37				26				46				169
Expiring warranties/claimed satisfied			(41	)			(61	)			(143	)			(151	)
Total			135				256				135				256
Less: current portion			(107	)			(179	)			(107	)			(179	)
Total long-term accrued warranty costs		$	28			$	77			$	28			$	77

		September 30, 2020
Term notes			2,528
Less: current portion			(1,134	)
Total long-term debt		$	1,394

Issue Date		Expiration Date		Total Warrants				Exercise Price
December 30, 2015		December 30, 2020			130,089			$	5.65
January 29, 2016		January 29, 2021			19,812			$	5.30
					149,901

		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Revenues		$	3,835			$	1,778			$	5,613
Costs of revenues			1,368				1,015				2,383
Gross profit			2,467				763				3,230
Gross profit %			64.3	%			42.9	%			57.5	%
Allocated operating expenses:
Engineering and product development			329				82				411
Selling and marketing			1,883				168				2,051
Unallocated operating expenses			-				-				1,929
			2,212				250				4,391
Income (loss) from operations			255				513				(1,161	)
Interest expense, net			-				-				(21	)
Income (loss) before income taxes		$	255			$	513			$	(1,182	)

		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Revenues		$	12,332			$	4,041			$	16,373
Costs of revenues			4,534				2,246				6,780
Gross profit			7,798				1,795				9,593
Gross profit %			63.2	%			44.4	%			58.6	%
Allocated operating expenses:
Engineering and product development			828				122				950
Selling and marketing			6,021				425				6,446
Unallocated operating expenses			-				-				5,921
			6,849				547				13,317
Income (loss) from operations			949				1,248				(3,724	)
Interest expense, net			-				-				(38	)
Income (loss) before income taxes		$	949			$	1,248			$	(3,762	)

		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Revenues		$	5,991			$	1,489			$	7,480
Costs of revenues			1,966				889				2,855
Gross profit			4,025				600				4,625
Gross profit %			67.2	%			40.3	%			61.8	%
Allocated operating expenses:
Engineering and product development			226				23				249
Selling and marketing			2,762				125				2,887
Unallocated operating expenses			-				-				2,218
			2,988				148				5,354
Income (loss) from operations			1,037				452				(729	)
Interest expense, net			-				-				(153	)
Income (loss) before income taxes		$	1,037			$	452			$	(882	)

		Dermatology Recurring Procedures				Dermatology Procedures Equipment				TOTAL
Revenues		$	17,142			$	5,546			$	22,688
Costs of revenues			5,492				3,052				8,544
Gross profit			11,650				2,494				14,144
Gross profit %			68.0	%			45.0	%			62.3	%
Allocated operating expenses:
Engineering and product development			666				122				788
Selling and marketing			8,301				610				8,911
Unallocated operating expenses			-				-				7,398
			8,967				732				17,097
Income (loss) from operations			2,683				1,762				(2,953	)
Interest expense, net			-				-				(433	)
Income (loss) before income taxes		$	2,683			$	1,762			$	(3,386	)

For the three and nine months ended September 30, 2019, revenues from sales to the Company’s international master distributor were $1,050 and $4,407, or 14% and 19%, respectively, of total revenues for such period.

For the year ending December 31,		Amount
Remaining 2020		$	115
2021			456
2022			371
2023			242
2024			186
Total remaining lease payments			1,370
Less: imputed interest			(205	)
Total lease liabilities		$	1,165

	•	XTRAC® Excimer Laser. XTRAC received FDA clearance in 2000 and has since become a widely recognized treatment among dermatologists for psoriasis and other skin diseases. The XTRAC System delivers ultra-narrowband ultraviolet B (“UVB”) light to affected areas of skin. Following a series of treatments typically performed twice weekly, psoriasis remission can be achieved, and vitiligo patches can be re-pigmented. XTRAC is endorsed by the National Psoriasis Foundation, and its use for psoriasis is covered by nearly all major insurance companies, including Medicare. We estimate that more than half of all major insurance companies now offer reimbursement for vitiligo as well, a figure that is increasing.
	•	In the third quarter of 2018, we announced the FDA granted clearance for our Multi Micro Dose (MMD) tip for our XTRAC excimer laser. The MMD Tip accessory is indicated for use in conjunction with the XTRAC laser system to filter the Narrow Band UVB (“NB-UVB”) light at delivery in order to calculate and individualize the maximum non-blistering dose for a particular patient.
	•	In the third quarter of 2018, we announced the launch of our S3®, the next generation XTRAC. The S3 is smaller, faster and has a smart user interface.
	•	In January 2020, we announced the FDA granted clearance of our XTRAC Momentum Excimer Laser Platform.
	•	VTRAC® Lamp. VTRAC received FDA clearance in 2005 and provides targeted therapeutic efficacy demonstrated by excimer technology with the simplicity of design and reliability of a lamp system.

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2020				2019				2020				2019
Dermatology Recurring Procedures		$	3,835			$	5,991			$	12,332			$	17,142
Dermatology Procedures Equipment			1,778				1,489				4,041				5,546
Total Revenues		$	5,613			$	7,480			$	16,373			$	22,688

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2020				2019				2020				2019
Dermatology Recurring Procedures		$	1,368			$	1,966			$	4,534			$	5,492
Dermatology Procedures Equipment			1,015				889				2,246				3,052
Total Cost of Revenues		$	2,383			$	2,855			$	6,780			$	8,544

Company Profit Analysis		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2020				2019				2020				2019
Revenues		$	5,613			$	7,480			$	16,373			$	22,688
Percent decrease			(25.0	)%							(27.8	)%
Cost of revenues			2,383				2,855				6,780				8,544
Percent decrease			(16.5	)%							(20.6	)%
Gross profit		$	3,230			$	4,625			$	9,593			$	14,144
Gross profit  percentage			57.5	%			61.8	%			58.6	%			62.3	%

Dermatology Recurring Procedures		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2020				2019				2020				2019
Revenues		$	3,835			$	5,991			$	12,332			$	17,142
Percent decrease			(35.9	)%							(28.1	)%
Cost of revenues			1,368				1,966				4,534				5,492
Percent decrease			(30.4	)%							(17.4	)%
Gross profit		$	2,467			$	4,025			$	7,798			$	11,650
Gross profit  percentage			64.3	%			67.2	%			63.2	%			68.0	%

Dermatology Procedures Equipment		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2020				2019				2020				2019
Revenues		$	1,778			$	1,489			$	4,041			$	5,546
Percent increase (decrease)			19.4	%							(27.1	)%
Cost of revenues			1,015				889				2,246				3,052
Percent increase (decrease)			14.2	%							(26.4	)%
Gross profit		$	763			$	600			$	1,795			$	2,494
Gross profit  percentage			42.9	%			40.3	%			44.4	%			45.0	%

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2020				2019				2020				2019
Net Loss		$	(1,254	)		$	(860	)		$	(3,969	)		$	(3,275	)
Adjustments:
Depreciation/amortization*			890				1,183				3,035				3,677
Income taxes			72				(22	)			207				(111	)
Interest expense, net			21				153				38				433
Non-GAAP EBITDA			(271	)			454				(689	)			724
Stock compensation			403				257				1,243				883
Non-GAAP adjusted EBITDA		$	132			$	711			$	554			$	1,607

•	forecasts of future business performance, consumer trends and macro-economic conditions, including the timing and pace of physician practices opening back up and remaining open after the COVID-19 pandemic subsides and/or regional, statewide, or country-wide restrictions are re-imposed, and our ability and its effectiveness to stimulate recurring revenue by generating patient referrals to our provider customers
•	descriptions of market and/or competitive conditions;
•	descriptions of plans or objectives of management for future operations, products or services;
•	our estimates regarding the sufficiency of our cash resources, expenses, capital requirements and needs for additional financing, compliance with the terms of the PPP loan and related regulations, the terms of the EIDL loan and our ability to obtain additional financing;
•	our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;
•	our ability to obtain and maintain regulatory approvals of our products;
•	anticipated results of existing or future litigation;

•	health emergencies, the spread of infectious diseases; and
•	descriptions or assumptions underlying or related to any of the above items.

3.1		Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Registration Statement on Form S-3 (File No. 333-167113), as filed on May 26, 2010).
3.2		Fourth Amended and Restated Bylaws of the Company (Incorporated by reference to Exhibit 3.2 contained in our Form 8-K current report as filed on January 8, 2016).
3.3		Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2013 filed on August 7, 2013).
3.4		Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, filed on July 10, 2014).
3.5		Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, filed on February 3, 2014).
3.6		Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, filed on July 23, 2014).
3.7		Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, as filed on September 30, 2015).

3.8		Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, as filed on January 8, 2016).
3.9		Certificate of Designations of Series C Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 contained in our Current Report on Form 8-K, as filed on September 25, 2017).
10.1		Settlement Agreement and Release with RA Medical Systems, Inc. (Incorporated by reference to Exhibit 10.1 contained in our Current Report on Form 8-K, as filed on August 11, 2020).

31.1		Rule 13a-14(a) Certificate of Chief Executive Officer
31.2		Rule 13a-14(a) Certificate of Chief Financial Officer
32.1*		Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Schema
101.CAL		XBRL Taxonomy Calculation Linkbase
101.DEF		XBRL Taxonomy Definition Linkbase
101.LAB		XBRL Taxonomy Label Linkbase
101.PRE		XBRL Taxonomy Presentation Linkbase

*

The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

STRATA SKIN SCIENCES, INC.

Date   November 10, 2020	By:	/s/ Dolev Rafaeli
		Name  Dolev Rafaeli
		Title    President & Chief Executive Officer

Date   November 10, 2020	By:	/s/ Matthew C. Hill
		Name  Matthew C. Hill
		Title    Chief Financial Officer